Randomized comparison of FOLFIRI plus cetuximab versus FOLFIRI plus bevacizumab as first-line treatment of KRAS-wildtype metastatic colorectal cancer: German AIO study KRK-0306 (FIRE-3).
Volker Heinemann(Comprehensive Cancer Center Vienna), Sebastian Stintzing(University of Southern California), Alexander Kiani(Bayreuth Medical Center), Thomas Decker, Michael Scholz(Klinikum Stuttgart), Martina Stauch, Ursula Vehling‐Kaiser(University of Applied Sciences Landshut), Dominik Paul Modest, Joerg Hielscher(Klinikum Chemnitz), Andreas Jung(German Cancer Research Center), Christoph Kahl(Klinikum Magdeburg), Salah‐Eddin Al‐Batran(Krankenhaus Nordwest), Britta Schaefer(Westpfalz Klinikum), Tobias Heintges(Lukaskrankenhaus), Ludwig Fischer von Weikersthal(Klinikum St. Marien Amberg), Werner Scheithauer(Comprehensive Cancer Center Vienna), G. Seipelt, Juergen Lerchenmueller(Praxis für Hämatologie und Onkologie), Frank Kullmann(Klinikum Weiden), Sebastian Mueller
Cited by 102
Related Papers
Perioperative chemotherapy with FOLFOX4 and surgery versus surgery alone for resectable liver metastases from colorectal cancer (EORTC Intergroup trial 40983): a randomised controlled trial
|The Lancet|2008|1.9k
FOLFIRI plus cetuximab versus FOLFIRI plus bevacizumab as first-line treatment for patients with metastatic colorectal cancer (FIRE-3): a randomised, open-label, phase 3 trial
|The Lancet Oncology|2014|1.7k